SM
BCTXZ

Sabby Management’s BriaCell Therapeutics Corp Warrant BCTXZ Stock Holding History

Sabby Management’s Portfolio BCTXZ Stock Details BCTXZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5K Sell
120,802
-85,951
-42% -$8.36K 0.01% 23
2026
Q1 		$28.9K Sell
206,753
-59,211
-22% -$9.94K 0.06% 27
2025
Q4 		$77.2K Sell
265,964
-108,524
-29% -$40.4K 0.11% 28
2025
Q3 		$125K Sell
374,488
-224,255
-37% -$74.3K 0.15% 27
2025
Q2 		$635K Buy
+598,743
New +$646K 1.15% 14

Other funds holding BCTXZ

HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Sabby Management's BCTXZ Position: Q2 2026 in Review

Sabby Management reduced its BriaCell Therapeutics Corp Warrant (BCTXZ) stake by 42% in Q2 2026, selling an estimated $8.36K and leaving 120,802 shares worth $11.5K. The position accounts for 0.01% of the portfolio, ranked #23.

Sabby Management first reported a position in BCTXZ in Q2 2025 and has held it in 5 quarters since. The position peaked at $635K in Q2 2025. 5 funds tracked by Wall St. Rank hold BCTXZ as of Q2 2026.

  • Sabby Management held 120,802 shares of BriaCell Therapeutics Corp Warrant worth $11.5K as of Q2 2026.
  • Sabby Management sold 85,951 BriaCell Therapeutics Corp Warrant shares in Q2 2026, an estimated $8.36K.
  • BriaCell Therapeutics Corp Warrant made up 0.01% of Sabby Management's portfolio in Q2 2026, its #23 holding.
  • Sabby Management first reported a position in BriaCell Therapeutics Corp Warrant in Q2 2025 and has held it in 5 quarters since.
  • Sabby Management's BriaCell Therapeutics Corp Warrant position peaked at $635K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.